PA8525401A1 - Compuestos farmaceuticos - Google Patents

Compuestos farmaceuticos

Info

Publication number
PA8525401A1
PA8525401A1 PA20018525401A PA8525401A PA8525401A1 PA 8525401 A1 PA8525401 A1 PA 8525401A1 PA 20018525401 A PA20018525401 A PA 20018525401A PA 8525401 A PA8525401 A PA 8525401A PA 8525401 A1 PA8525401 A1 PA 8525401A1
Authority
PA
Panama
Prior art keywords
compounds
affections
pharmaceutical compounds
maintenance
ifata
Prior art date
Application number
PA20018525401A
Other languages
English (en)
Inventor
Julian Blagg
Mark Edward Bunnage
Allerton Charlotte Moira Norfor
John Steele
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0020346A external-priority patent/GB0020346D0/en
Priority claimed from GB0027409A external-priority patent/GB0027409D0/en
Priority claimed from GB0029556A external-priority patent/GB0029556D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PA8525401A1 publication Critical patent/PA8525401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA COMPUESTOS DE FORMULA (I) ESTOS COMPUESTOS SON UNA CLASE DE INHIBIDORRES DE IFATa. DICHOS COMPUESTOS SON ADECUADOS PARA USO EN EL TRATAMIENTO DE AFECCIONES TALES COMO TROMBOSIS, ATEROSCLEROSIS, ADHERENCIAS, CICATRICES DERMICAS, CANCER, AFECCIONES FIBROTICAS, ENFERMEDADES INFLAMATORIAS Y AQUELLAS AFECCIONES QUE SE BENEFICIAN DEL MANTENIMIENTO O LA POTENCIACION DE LOS NIVELES DE BRADIQUININA EN EL CUERPO.
PA20018525401A 2000-08-17 2001-08-14 Compuestos farmaceuticos PA8525401A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0020346A GB0020346D0 (en) 2000-08-17 2000-08-17 Pharmaceuticals
GB0027409A GB0027409D0 (en) 2000-11-09 2000-11-09 Pharmaceuticals
GB0029556A GB0029556D0 (en) 2000-12-04 2000-12-04 Pharmaceuticals

Publications (1)

Publication Number Publication Date
PA8525401A1 true PA8525401A1 (es) 2002-04-25

Family

ID=27255849

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20018525401A PA8525401A1 (es) 2000-08-17 2001-08-14 Compuestos farmaceuticos

Country Status (38)

Country Link
EP (1) EP1311488B1 (es)
JP (2) JP4119746B2 (es)
KR (1) KR20030022412A (es)
CN (1) CN1443173A (es)
AP (1) AP1375A (es)
AR (1) AR035580A1 (es)
AT (1) ATE447557T1 (es)
AU (1) AU2001276605A1 (es)
BG (1) BG107330A (es)
BR (1) BR0113289A (es)
CA (1) CA2419633C (es)
CY (1) CY1109693T1 (es)
CZ (1) CZ2003388A3 (es)
DE (1) DE60140368D1 (es)
DK (1) DK1311488T3 (es)
DO (1) DOP2001000233A (es)
EA (1) EA005532B1 (es)
EE (1) EE200300070A (es)
ES (1) ES2334101T3 (es)
HR (1) HRP20030103A2 (es)
HU (1) HUP0303763A3 (es)
IL (1) IL153225A0 (es)
IS (1) IS6638A (es)
MA (1) MA26940A1 (es)
MX (1) MXPA03001425A (es)
NO (1) NO20030706L (es)
NZ (1) NZ522823A (es)
OA (1) OA12362A (es)
PA (1) PA8525401A1 (es)
PE (1) PE20020352A1 (es)
PL (1) PL361054A1 (es)
PT (1) PT1311488E (es)
SI (1) SI1311488T1 (es)
SK (1) SK1732003A3 (es)
SV (1) SV2002000602A (es)
TN (1) TNSN01126A1 (es)
UY (1) UY26889A1 (es)
WO (1) WO2002014285A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103272D0 (sv) 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
US6713496B2 (en) 2002-01-22 2004-03-30 Pfizer Inc 3-(imidazolyl)-2-alkoxypropanoic acids
AP2004003084A0 (en) * 2002-01-22 2004-09-30 Pfizer 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
CA2472239A1 (en) * 2002-01-22 2003-07-31 Pfizer Inc. 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases
CA2524222C (en) * 2003-04-29 2012-02-07 Roger Alberto N.epsilon. and/or n.alpha. derivatized, metal and organic protected l-histidine for coupling to biomolecules for highly efficient labeling with [m(oh2)3(co)3]+ by fac coordination
SE0302853D0 (sv) * 2003-10-29 2003-10-29 Astrazeneca Ab Chemical compounds
EP1680120A2 (en) * 2003-11-03 2006-07-19 Probiodrug AG Combinations useful for the treatment of neuronal disorders
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
US20060234986A1 (en) * 2005-04-18 2006-10-19 Schering Aktiengesellschaft Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI
DE102005049385A1 (de) * 2005-10-15 2007-04-19 Sanofi-Aventis Deutschland Gmbh Imidazolderivate als Inhibitoren von TAFIa
MX2009005516A (es) * 2006-12-06 2009-06-04 Sanofi Aventis Derivados de urea y de sulfamida en calidad de inhibidores de tafia.
EP2262783A2 (en) * 2008-02-21 2010-12-22 Sanofi-Aventis Covalently binding imaging probes
WO2010050525A1 (ja) * 2008-10-29 2010-05-06 大正製薬株式会社 ＴＡＦＩａ阻害活性を有する化合物
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP5778133B2 (ja) * 2010-03-18 2015-09-16 第一三共株式会社 シクロプロパンカルボン酸誘導体
BR112012017474A2 (pt) * 2010-03-18 2016-04-19 Daiichi Sankyo Co Ltd composto, sal farmacologicamente aceitável do composto, droga farmacêutica, inibidor da fibrinólise ativável por trombina, promotor da fibrinólise, droga preventiva ou terapêutica, composição farmacêutica, uso de uma composição farmacêutica, inibidor de tafia para injeção, e, uso de uma composição farmacêutica
GEP201706614B (en) * 2011-05-17 2017-02-10 Pharmasyntez Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
EP2734508B1 (en) * 2011-07-22 2018-02-28 Cambrex Karlskoga Ab New processes for preparing 4-substituted imidazoles
WO2013039202A1 (ja) * 2011-09-15 2013-03-21 第一三共株式会社 新規アクリル酸誘導体
KR20160018557A (ko) 2013-06-10 2016-02-17 사노피 TAFIa의 저해제로서의 마크로사이클릭 우레아 유도체, 이의 제법 및 의약품으로서의 이의 용도
PT3359528T (pt) 2015-10-07 2022-04-07 Salk Inst Biological Studies Agonistas de ppar, compostos, composições farmacêuticas e métodos de utilização dos mesmos
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3437641A4 (en) 2016-03-29 2019-11-20 Daiichi Sankyo Company, Limited THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASES
KR102430906B1 (ko) 2016-04-13 2022-08-10 미토브리지, 인크. Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6163661A (ja) * 1984-09-05 1986-04-01 Microbial Chem Res Found ヒスタジン関連化合物
US5993815A (en) * 1996-11-08 1999-11-30 University Of Vermont Methods and compositions for inhibiting the activation of thrombin-activatable fibrinolysis inhibitor (TAFI)
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds

Also Published As

Publication number Publication date
ATE447557T1 (de) 2009-11-15
AP1375A (en) 2005-03-03
NO20030706D0 (no) 2003-02-14
CA2419633C (en) 2011-05-10
IL153225A0 (en) 2003-07-06
SI1311488T1 (sl) 2010-01-29
JP4778531B2 (ja) 2011-09-21
PT1311488E (pt) 2009-12-30
AU2001276605A1 (en) 2002-02-25
BG107330A (en) 2003-06-30
SK1732003A3 (en) 2004-08-03
UY26889A1 (es) 2002-03-22
MXPA03001425A (es) 2003-06-06
IS6638A (is) 2002-11-28
ES2334101T3 (es) 2010-03-05
TNSN01126A1 (fr) 2005-11-10
DE60140368D1 (de) 2009-12-17
EP1311488B1 (en) 2009-11-04
CN1443173A (zh) 2003-09-17
JP4119746B2 (ja) 2008-07-16
KR20030022412A (ko) 2003-03-15
CZ2003388A3 (cs) 2004-03-17
CY1109693T1 (el) 2014-08-13
BR0113289A (pt) 2003-06-17
WO2002014285A1 (en) 2002-02-21
PE20020352A1 (es) 2002-05-11
JP2008169224A (ja) 2008-07-24
NZ522823A (en) 2004-11-26
HRP20030103A2 (en) 2003-04-30
DOP2001000233A (es) 2002-05-15
PL361054A1 (en) 2004-09-20
HUP0303763A2 (hu) 2004-04-28
EA005532B1 (ru) 2005-04-28
JP2004506044A (ja) 2004-02-26
SV2002000602A (es) 2002-10-24
AP2001002250A0 (en) 2001-09-30
EP1311488A1 (en) 2003-05-21
NO20030706L (no) 2003-04-15
EE200300070A (et) 2005-02-15
HUP0303763A3 (en) 2004-06-28
OA12362A (en) 2004-04-07
DK1311488T3 (da) 2010-01-04
EA200201239A1 (ru) 2003-08-28
AR035580A1 (es) 2004-06-16
MA26940A1 (fr) 2004-12-20
CA2419633A1 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
PA8525401A1 (es) Compuestos farmaceuticos
CL2018002924A1 (es) Inhibidores de bromodominios
UY28691A1 (es) Derivados de difenilazetidona
PA8583101A1 (es) Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf)
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
PA8583401A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
HN2003000039A (es) 2-(PIRIMIDIN-2-ILAMINO)-PIRIDO[2,3-d]PIRIMIDIN-7-ONAS
UY27882A1 (es) Compuestos quimicos
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CO2019009722A2 (es) Dendrímeros terapéuticos
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
CY1106026T1 (el) Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας
CL2022000005A1 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
CL2021003568A1 (es) Compuestos heteroaromáticos como inhibidores de vanina (divisional de solicitud n° 202101198)
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
UY27452A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
ES2164899T3 (es) Uso de alcaloides de la clase lamellarina en metodos de tratamiento.
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso